- What has been your biggest challenge working on m2M project?
I can mainly think of the benefits of working on m2M project: very well structured and organized project with clear deliverables and dependencies of group members. Some budgets are however a bit limited for enough validation capacity to perform cell-based manufacturing processes. This will be a challenge towards the end of the project.
2. How do you think the m2M project can make a difference in the bioprinting field?
By a strong concentration of competence derived from different companies and academic settings, working together in one project.
3. In your opinion, how can the project help patients and strength the European biomanufacturing capacity while fostering collaboration between industry and clinicians?
This project drives the available technical knowledge for manufacturing through bioprinting towards a clinical setting. Collaboration with clinicians is not the main focus of the Working Packages and could be more strengthened towards the end of the project.
4. For you, what is the main result that m2M will deliver?
Innovative technology getting closer to clinical application.
5. We reached the 1-year mark of the project; how do you see the progress made?
All groups showed significant progress and new data on the consortium meeting and on the Work Package meetings.